These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 30010924)

  • 1. Disease modelling and drug discovery for hypertrophic cardiomyopathy using pluripotent stem cells: how far have we come?
    Lam CK; Wu JC
    Eur Heart J; 2018 Nov; 39(43):3893-3895. PubMed ID: 30010924
    [No Abstract]   [Full Text] [Related]  

  • 2. CRISPR/Cas9 editing in human pluripotent stem cell-cardiomyocytes highlights arrhythmias, hypocontractility, and energy depletion as potential therapeutic targets for hypertrophic cardiomyopathy.
    Mosqueira D; Mannhardt I; Bhagwan JR; Lis-Slimak K; Katili P; Scott E; Hassan M; Prondzynski M; Harmer SC; Tinker A; Smith JGW; Carrier L; Williams PM; Gaffney D; Eschenhagen T; Hansen A; Denning C
    Eur Heart J; 2018 Nov; 39(43):3879-3892. PubMed ID: 29741611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Isogenic models of hypertrophic cardiomyopathy unveil differential phenotypes and mechanism-driven therapeutics.
    Bhagwan JR; Mosqueira D; Chairez-Cantu K; Mannhardt I; Bodbin SE; Bakar M; Smith JGW; Denning C
    J Mol Cell Cardiol; 2020 Aug; 145():43-53. PubMed ID: 32531470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generation of iPSC line from MYH7 R403L mutation carrier with severe hypertrophic cardiomyopathy and isogenic CRISPR/Cas9 corrected control.
    Fontaine V; Duboscq-Bidot L; Jouve C; Hamlin M; Curjol A; Briand V; Janiak P; Hulot JS; Pruniaux-Harnist MP; Charron P; Villard E
    Stem Cell Res; 2021 Apr; 52():102245. PubMed ID: 33610018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inducible Pluripotent Stem Cell-Derived Cardiomyocytes Reveal Aberrant Extracellular Regulated Kinase 5 and Mitogen-Activated Protein Kinase Kinase 1/2 Signaling Concomitantly Promote Hypertrophic Cardiomyopathy in RAF1-Associated Noonan Syndrome.
    Jaffré F; Miller CL; Schänzer A; Evans T; Roberts AE; Hahn A; Kontaridis MI
    Circulation; 2019 Jul; 140(3):207-224. PubMed ID: 31163979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induced Pluripotent Stem Cell-Derived Cardiomyocytes from a Patient with MYL2-R58Q-Mediated Apical Hypertrophic Cardiomyopathy Show Hypertrophy, Myofibrillar Disarray, and Calcium Perturbations.
    Zhou W; Bos JM; Ye D; Tester DJ; Hrstka S; Maleszewski JJ; Ommen SR; Nishimura RA; Schaff HV; Kim CS; Ackerman MJ
    J Cardiovasc Transl Res; 2019 Oct; 12(5):394-403. PubMed ID: 30796699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modelling diastolic dysfunction in induced pluripotent stem cell-derived cardiomyocytes from hypertrophic cardiomyopathy patients.
    Wu H; Yang H; Rhee JW; Zhang JZ; Lam CK; Sallam K; Chang ACY; Ma N; Lee J; Zhang H; Blau HM; Bers DM; Wu JC
    Eur Heart J; 2019 Dec; 40(45):3685-3695. PubMed ID: 31219556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intronic CRISPR Repair in a Preclinical Model of Noonan Syndrome-Associated Cardiomyopathy.
    Hanses U; Kleinsorge M; Roos L; Yigit G; Li Y; Barbarics B; El-Battrawy I; Lan H; Tiburcy M; Hindmarsh R; Lenz C; Salinas G; Diecke S; Müller C; Adham I; Altmüller J; Nürnberg P; Paul T; Zimmermann WH; Hasenfuss G; Wollnik B; Cyganek L
    Circulation; 2020 Sep; 142(11):1059-1076. PubMed ID: 32623905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human-induced pluripotent stem cells for modelling metabolic perturbations and impaired bioenergetics underlying cardiomyopathies.
    Ramachandra CJA; Chua J; Cong S; Kp MMJ; Shim W; Wu JC; Hausenloy DJ
    Cardiovasc Res; 2021 Feb; 117(3):694-711. PubMed ID: 32365198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generation of two iPSC clones (MHHi021-A and MHHi021-B) from a patient with hypertrophic cardiomyopathy with p.Arg723Gly mutation in the MYH7 gene.
    Merkert S; Wunderlich S; Beier J; Franke A; Schwanke K; Göhring G; Kraft T; Francino A; Zweigerdt R; Martin U
    Stem Cell Res; 2021 Apr; 52():102208. PubMed ID: 33578365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Untangling the Biology of Genetic Cardiomyopathies with Pluripotent Stem Cell Disease Models.
    Buikema JW; Wu SM
    Curr Cardiol Rep; 2017 Apr; 19(4):30. PubMed ID: 28315121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generation of bi-allelic MYBPC3 truncating mutant and isogenic control from an iPSC line of a patient with hypertrophic cardiomyopathy.
    Warnecke N; Ulmer BM; Laufer SD; Shibamiya A; Krämer E; Neuber C; Hanke S; Behrens C; Loos M; Münch J; Kühnisch J; Klaassen S; Eschenhagen T; Patten-Hamel M; Carrier L; Mearini G
    Stem Cell Res; 2021 Aug; 55():102489. PubMed ID: 34375846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isogenic Pairs of hiPSC-CMs with Hypertrophic Cardiomyopathy/LVNC-Associated ACTC1 E99K Mutation Unveil Differential Functional Deficits.
    Smith JGW; Owen T; Bhagwan JR; Mosqueira D; Scott E; Mannhardt I; Patel A; Barriales-Villa R; Monserrat L; Hansen A; Eschenhagen T; Harding SE; Marston S; Denning C
    Stem Cell Reports; 2018 Nov; 11(5):1226-1243. PubMed ID: 30392975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modeling Hypertrophic Cardiomyopathy: Mechanistic Insights and Pharmacological Intervention.
    Mosqueira D; Smith JGW; Bhagwan JR; Denning C
    Trends Mol Med; 2019 Sep; 25(9):775-790. PubMed ID: 31324451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Divergent effects of adrenaline in human induced pluripotent stem cell-derived cardiomyocytes obtained from hypertrophic cardiomyopathy.
    Prajapati C; Ojala M; Aalto-Setälä K
    Dis Model Mech; 2018 Feb; 11(2):. PubMed ID: 29361520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human Engineered Cardiac Tissues Created Using Induced Pluripotent Stem Cells Reveal Functional Characteristics of BRAF-Mediated Hypertrophic Cardiomyopathy.
    Cashman TJ; Josowitz R; Johnson BV; Gelb BD; Costa KD
    PLoS One; 2016; 11(1):e0146697. PubMed ID: 26784941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modeling hypertrophic cardiomyopathy with human cardiomyocytes derived from induced pluripotent stem cells.
    Li J; Feng X; Wei X
    Stem Cell Res Ther; 2022 Jun; 13(1):232. PubMed ID: 35659761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generation of an induced pluripotent stem cell line from a hypertrophic cardiomyopathy patient with a pathogenic myosin binding protein C (MYBPC3) p.Arg502Trp mutation.
    Holliday M; Ross SB; Lim S; Semsarian C
    Stem Cell Res; 2018 Dec; 33():56-59. PubMed ID: 30316040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new diastolic dysfunction disease-modelling platform.
    Chatterjee S; Thum T
    Eur Heart J; 2019 Dec; 40(45):3696-3698. PubMed ID: 31274156
    [No Abstract]   [Full Text] [Related]  

  • 20. Cardiomyopathy phenotypes in human-induced pluripotent stem cell-derived cardiomyocytes-a systematic review.
    Eschenhagen T; Carrier L
    Pflugers Arch; 2019 May; 471(5):755-768. PubMed ID: 30324321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.